Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 474

Results For "IT"

10515 News Found

Bayer acquires Attralus’ cardiac amyloidosis imaging agents
News | January 16, 2026

Bayer acquires Attralus’ cardiac amyloidosis imaging agents

The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology


EMA and FDA unveil joint AI principles to transform drug revelopment
R&D | January 16, 2026

EMA and FDA unveil joint AI principles to transform drug revelopment

Experts caution that realizing AI’s potential requires careful management and risk mitigation


Alphatec and Theradaptive forge landmark spine partnership as Series B round launches
News | January 16, 2026

Alphatec and Theradaptive forge landmark spine partnership as Series B round launches

ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications


AVEO Oncology doses first patient in pioneering AML clinical trial
Clinical Trials | January 16, 2026

AVEO Oncology doses first patient in pioneering AML clinical trial

The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy


Gabby Union-Wade fronts Bayer's new menopause drug, Lynkuet
News | January 16, 2026

Gabby Union-Wade fronts Bayer's new menopause drug, Lynkuet

The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign


FDA finds no clear link between popular diabetes, weight-loss drugs and suicidal thoughts
News | January 16, 2026

FDA finds no clear link between popular diabetes, weight-loss drugs and suicidal thoughts

The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts


BioNTech maps pivotal oncology milestones for 2026
News | January 15, 2026

BioNTech maps pivotal oncology milestones for 2026

BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company


CARsgen and Dispatch Bio launch groundbreaking CAR T collaboration in China
Clinical Trials | January 15, 2026

CARsgen and Dispatch Bio launch groundbreaking CAR T collaboration in China

CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies